Glomerular Hyperfiltration Linked to Higher Mortality in Stroke and TIA Patients

This individual patient data meta-analysis of prospective cohort studies investigated the association between glomerular hyperfiltration and adverse outcomes in patients with stroke or transient ischemic attack (TIA). The analysis included 11,175 patients from prospective cohort studies. Glomerular hyperfiltration was defined as an estimated glomerular filtration rate (eGFR) above the age- and sex-adjusted 95th percentile, while the comparator group had normofiltration (absence of hyperfiltration and eGFR ≥ 60 mL/min/1.73 m²). The primary outcome was all-cause death, and secondary outcomes included any stroke and vascular death.

For the primary outcome of all-cause death, the hyperfiltration group had a significantly higher rate: 147 per 1000 person-years (95% CI, 119-180) versus 61 per 1000 person-years (95% CI, 57-66) in the normofiltration group. The adjusted hazard ratio was 1.76 (95% CI, 1.46-2.11; P < .001), indicating a 76% increased risk of death. For vascular death, the adjusted HR was 1.68 (95% CI, 1.29-2.17; P < .001), also showing a significantly higher risk in the hyperfiltration group. Absolute rates for vascular death were not reported. Results for any stroke were not provided in the available data.

Safety and tolerability data were not reported in this meta-analysis, as it focused on outcomes rather than adverse events. The study did not report on adverse events, serious adverse events, discontinuations, or tolerability.

Compared to prior studies, this meta-analysis adds to the growing evidence that kidney function abnormalities, specifically hyperfiltration, may be a risk marker in stroke populations. Previous research has focused more on reduced eGFR as a risk factor, but hyperfiltration has been less studied. This analysis provides robust data from multiple cohorts with individual patient data, enhancing statistical power and generalizability.

Key methodological limitations include the observational nature of the included studies, which precludes causal inference. Although adjustments were made for confounders, residual confounding is possible. The study did not report specific limitations, but typical concerns include potential unmeasured confounders, variability in eGFR measurement across cohorts, and lack of data on medication use or comorbidities that could influence outcomes. Additionally, the follow-up duration was not reported, which may affect the interpretation of event rates.

Clinically, these findings suggest that glomerular hyperfiltration may be a marker of increased risk for death and vascular death in patients with ischemic stroke or TIA. However, given the observational design, clinicians should not assume a causal relationship. It may be prudent to monitor kidney function in stroke patients and consider hyperfiltration as a potential risk indicator, but no specific interventions can be recommended based on this study alone.

Several questions remain unanswered. The mechanisms linking hyperfiltration to adverse outcomes are unclear; it may reflect underlying vascular damage, hemodynamic stress, or other pathophysiological processes. Whether interventions that reduce hyperfiltration (e.g., renin-angiotensin system blockers) improve outcomes in this population is unknown. The association with recurrent stroke was not reported, and the impact of hyperfiltration on other outcomes such as cardiovascular events or renal decline requires further study. Future research should also explore whether hyperfiltration is a modifiable risk factor or merely a marker of disease severity.